A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time,
becoming the number one cancer in the world. HER2 is an important prognostic indicator and
therapeutic target for breast cancer. HER2-overexpressing breast cancer accounts for about
20% to 30% of all breast cancer patients. Targeted therapy for HER2 protein is the core
treatment for this type of breast cancer. At present, the neoadjuvant treatment mode of
trastuzumab and pertuzumab dual-target chemotherapy has become the standard neoadjuvant
treatment for high-risk HER2-positive breast cancer. For patients with early-stage high-risk
or locally advanced HER2-positive breast cancer, whether standard neoadjuvant regimen without
anthracycline can achieve the same therapeutic effect compared with regimen containing
anthracycline is still inconclusive.Therefore, this study aimed to compare the efficacy and
safety of two neoadjuvant treatment regimens, TCbHP*6 and ECHP*4-THP*4, in the neoadjuvant
treatment of HER2-positive breast cancer through a randomized controlled phase 3 clinical
trial.